Analyst Ranking
Top 23%
#1170 out of 5279 analysts
Average Return
+7.66%
Win Rate
46%26 out of 56
Risk vs Reward
Poor
Good

Uy Ear's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Arcutis Biotherapeutics IncARQT
+306.12%$3.43$13.93
2024-01-02 -
2024-12-31
Strong Buy
Arcutis Biotherapeutics IncARQT
+272.38%$3.91$14.56
2024-01-02 -
2025-01-02
Strong Buy
Mbx Biosciences IncMBX
+154.31%$11.95$30.39
2025-08-04 -
2026-05-19
Buy
Cabaletta Bio IncCABA
+131.36%$8.10$18.74
2023-03-16 -
2024-03-15
Strong Buy
Arcutis Biotherapeutics IncARQT
+104.31%$13.22$27.01
2025-02-25 -
2026-02-25
Buy

Uy Ear Analyst Color

Get additional color on Uy Ear's coverage of popular stocks

Uy Ear's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Relmada Therapeutics IncRLMD
3Buy$19.00+170.27%Maintains
2 months ago
Sarepta Therapeutics IncSRPT
9Buy$31.00+86.30%Maintains
2 months ago
Uniqure NvQURE
8Buy$35.00+41.76%Upgrades
2 months ago
Arcutis Biotherapeutics IncARQT
15Buy$35.00+79.49%Maintains
3 months ago
Acadia Pharmaceuticals IncACAD
16Buy$35.00+70.90%Upgrades
3 months ago
Neurocrine Biosciences IncNBIX
10Hold$175.00+13.37%Maintains
5 months ago
Evolus IncEOLS
4Buy$19.00+195.49%Maintains
6 months ago
Alkermes PLCALKS
6Buy$45.00+21.62%Maintains
7 months ago
Mbx Biosciences IncMBX
2Buy$56.00+84.27%Maintains
8 months ago
Tectonic Therapeutic IncTECX
6Buy$85.00N/AMaintains
a year ago
Sage Therapeutics IncSAGE
2Hold$16.00N/AMaintains
2 years ago
Cartesian Therapeutics IncRNAC
3Strong Buy$40.00N/AInitiates Coverage On
2 years ago
Revance Therapeutics IncRVNC
1Strong Buy$16.00N/AMaintains
2 years ago
Johnson & JohnsonJNJ
1Strong Buy$40.00N/AMaintains
3 years ago
Satsuma Pharmaceuticals IncSTSA
1Hold$2.00N/AReiterates
3 years ago
Cabaletta Bio IncCABA
1Strong Buy$10.00N/AReiterates
3 years ago
Ocugen IncOCGN
2Strong Buy$3.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.